Thyrocare Q1FY27 PAT rises 34% to ₹51.33 crore on strong volume growth
Thyrocare Technologies reported a 34% year-on-year increase in consolidated net profit to ₹51.33 crore for Q1FY27, driven by a 24% rise in revenue to ₹240.02 crore. EBITDA grew 34% to ₹77.27 crore with margins expanding to 32.2%. The company processed 55.2 million tests, up 28%, and expanded into Specialty Diagnostics.
*this image is generated using AI for illustrative purposes only.
Thyrocare Technologies reported a 34% year-on-year increase in consolidated net profit to ₹51.33 crore for the quarter ended June 30, 2026 (Q1FY27), compared to ₹38.29 crore in the corresponding period of the previous year. The growth was driven by a 24% rise in revenue from operations, which reached ₹240.02 crore, up from ₹193.03 crore in Q1FY26. EBITDA for the quarter grew by 34% to ₹77.27 crore, with the margin expanding to 32.2% from 29.9% in the prior year, reflecting improved operational efficiency.
The company processed 55.2 million tests during the quarter, a 28% increase year-on-year, reinforcing its position as India's largest diagnostic test volume processor. The Pathology segment grew by 26%, with franchise revenue increasing 27% and partnership revenue rising 26%. Thyrocare also expanded into Specialty Diagnostics, commencing with Allergy and Genomics, while maintaining Six Sigma quality standards with complaints per million tests reducing to 3.1.
Financial Performance
The Board of Directors, at its meeting held on July 23, 2026, approved the unaudited standalone and consolidated financial results for the quarter. The results were reviewed by the statutory auditors, Price Waterhouse Chartered Accountants LLP, who issued an unmodified conclusion. The company's total expenses for the quarter stood at ₹176.59 crore on a consolidated basis, compared to ₹147.45 crore in the previous year.
The table below summarises the key financial metrics for the quarter:
| Metric | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations (Consolidated): | ₹240.02 crore | ₹193.03 crore | +24.3% |
| Net Profit (Consolidated): | ₹51.33 crore | ₹38.29 crore | +34.1% |
| EBITDA: | ₹77.27 crore | ₹57.77 crore | +33.8% |
| EBITDA Margin: | 32.2% | 29.9% | +230 bps |
| Basic EPS (Consolidated): | ₹3.23 | ₹2.41 | +34.0% |
Segment Performance
The group operates primarily through diagnostic testing services and imaging services. Diagnostic testing services remained the largest revenue contributor, generating ₹226.21 crore in segment revenue for the quarter. The imaging services segment reported revenue of ₹13.48 crore. The segment results before tax and exceptional items for the diagnostic testing services stood at ₹61.90 crore.
Corporate Governance
Based on the recommendation of the Audit Committee, the Board approved the re-appointment of M/s. Ernst & Young LLP, Chartered Accountants, as Internal Auditors of the company for the financial year 2026-27. The Board meeting commenced at 2:45 P.M. and concluded at 3:35 P.M. on July 23, 2026.
Historical Stock Returns for Thyrocare Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.28% | +2.83% | +0.08% | +19.05% | +37.75% | +24.51% |
How will the expansion into Specialty Diagnostics, specifically Allergy and Genomics, contribute to revenue diversification in the coming quarters?
Can the company sustain the 230 bps EBITDA margin expansion given the rising total expenses?
What strategies are in place to maintain the 28% volume growth rate as the market matures?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
